Simultaneous Resection of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases: Safety and Oncological Efficacy.

Fiche publication

Date publication

janvier 2022

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe , Pr IMPERIALE Alessio

Tous les auteurs :
Addeo P, Cusumano C, Goichot B, Guerra M, Faitot F, Imperiale A, Bachellier P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35158996

Résumé

Whether the simultaneous resection of pancreatic neuroendocrine tumors (PNET) with synchronous liver metastases (LM) is safe and oncologically efficacious remains to be debated. We retrospectively reviewed clinical data from patients who underwent the simultaneous resection of PNETs with LMs over the last 25 years. Fifty-one consecutive patients with a median age of 54 years (range 27-80 years) underwent pancreaticoduodenectomy (PD) ( = 16), distal pancreatosplenectomy (DSP) ( = 32) or total pancreatectomy ( = 3) with synchronous LM resection. There were no differences in the postoperative outcomes in term of mortality ( = 0.33) and morbidity ( = 0.76) between PD and DSP. The median overall survival (OS) was 64.78 months (95% CI: 49.7-119.8), and the overall survival rates at 1, 3, and 5 years were 97.9%, 86.2% and 61%, respectively. The OS varied according to the tumor grade (G): G1 (OS 128 months, 5-year OS 83%) vs. G2 (OS 60.5 months, 5-year OS 58%) vs. G3 (OS 49.7 months, 5-year OS 0%) ( = 0.03). Multivariate Cox analysis identified G as the only prognostic factor (HR: 5.56; 95% CI: 0.91-9.60; = 0.01). Simultaneous PNETS with LMs can be performed safely with acceptable morbidity and mortality at tertiary centers. Well-differentiated PNETs had longer survival and might benefit the most from these extended surgeries.